Category Archives: Global News Feed

REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Peter Soparkar, chief operating officer of Adverum Biotechnologies, will present at the Jefferies Cell and Genetic Medicine Summit on September 29, 2022, at 9:30 a.m. ET.

Continued here:
Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit

Carlsbad, CA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it had made equity grants to two new employees under its 2021 Inducement Plan.

See the original post:
Palisade Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Aug. 12, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for everyone and dedicated to developing health solutions for every person on our planet, today announced a private placement of approximately $109 million.

Original post:
GreenLight Biosciences announces $109 million financing

MALVERN, Pa., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will deliver a virtual presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17.

Continue reading here:
Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

—Longeveron’s Phase 2a trial of Lomecel-B for patients with mild Alzheimer’s Disease proceeding on schedule, currently at 50% enrollment

Excerpt from:
Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Acquisition will create a vertically integrated Colorado cannabis company, significantly accelerating Bespoke’s growth strategy

See the rest here:
Bespoke Extracts to Expand its Colorado Business and Capabilities with Acquisition of Best Day Ever